Sopharma AD-Sofia (WAR:SPH) EBIT: zł432 Mil (TTM As of Mar. 2026)


WAR:SPH Sopharma AD-Sofia WAR:SPH
67 GF Score
Price zł7.92
GF Value zł13.56
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Sopharma AD-Sofia EBIT?

Sopharma AD-Sofia WAR:SPH +8.49% 67 EBIT is zł432 Mil as of Mar. 2026. GuruFocus rates WAR:SPH with a GF Score™ of 67/100 and a GF Value™ of zł13.56 (Possible Value Trap). The stock has 3 warning signs investors should review.

Sopharma AD-Sofia's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was zł158 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was zł432 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Sopharma AD-Sofia's annualized ROC % for the quarter that ended in Mar. 2026 was 14.89%. Sopharma AD-Sofia's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 29.84%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Sopharma AD-Sofia's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 7.67%.


Sopharma AD-Sofia  (WAR:SPH) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Sopharma AD-Sofia's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=557.028 * ( 1 - 4.82% )/( (3503.054 + 3617.402)/ 2 )
=530.1792504/3560.228
=14.89 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4553.599 - 893.522 - ( 157.023 - max(0, 1896.19 - 2397.479+157.023))
=3503.054

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4553.874 - 842.457 - ( 94.015 - max(0, 1740.398 - 2397.785+94.015))
=3617.402

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Sopharma AD-Sofia's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=630.524/( ( (894.314 + max(1166.133, 0)) + (887.996 + max(1277.157, 0)) )/ 2 )
=630.524/( ( 2060.447 + 2165.153 )/ 2 )
=630.524/2112.8
=29.84 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(904.976 + 1106.693 + 163.702) - (893.522 + 0 + 115.716)
=1166.133

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(931.48 + 1128.04 + 150.842) - (842.457 + 0 + 90.748)
=1277.157

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Sopharma AD-Sofia's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=432.183/5636.992
=7.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sopharma AD-Sofia EBIT Related Terms


Sopharma AD-Sofia EBIT Historical Data

* Premium members only.

The historical data trend for Sopharma AD-Sofia's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sopharma AD-Sofia EBIT Chart

Sopharma AD-Sofia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 229.24 179.97 249.41 208.79 394.55

Sopharma AD-Sofia Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 109.77 90.06 113.69 70.80 157.63

WAR:SPH vs MCK, COR, CAH: EBIT Comparison

For the Medical Distribution subindustry, Sopharma AD-Sofia's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sopharma AD-Sofia EV-to-EBIT vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sopharma AD-Sofia's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sopharma AD-Sofia's EV-to-EBIT falls into.


WAR:SPH
67GF Score
Sopharma AD-Sofia WAR:SPH
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sopharma AD-Sofia EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł432 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of zł432 Mil mean?
Sopharma AD-Sofia (WAR:SPH) has a EBIT of zł432 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Sopharma AD-Sofia.
Is Sopharma AD-Sofia's EBIT too high?
Sopharma AD-Sofia's current EBIT is zł432 Mil. Overall, Sopharma AD-Sofia has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sopharma AD-Sofia's EBIT compare to MCK and COR?
Sopharma AD-Sofia's EBIT of zł432 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Distribution company?
A good EBIT depends on the Medical Distribution industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Sopharma AD-Sofia. Sopharma AD-Sofia's current EBIT is zł432 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma AD-Sofia stock overvalued right now?
Based on GuruFocus' analysis, Sopharma AD-Sofia (WAR:SPH) is currently considered Possible Value Trap. The stock's GF Value™ is zł13.56, compared to a current price of zł7.92 — trading 41.6% below its estimated fair value. The current EBIT is zł432 Mil. Sopharma AD-Sofia's overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Sopharma AD-Sofia (WAR:SPH), the current EBIT is zł432 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sopharma AD-Sofia (WAR:SPH) Overvalued in 2026?

Based on GuruFocus' analysis, Sopharma AD-Sofia stock appears to be undervalued. The current stock price of zł7.92 is trading 41.6% below its estimated GF Value™ of zł13.56. GuruFocus considers Sopharma AD-Sofia to be Possible Value Trap.

Key valuation signals for WAR:SPH:

  • EBIT: zł432 Mil
  • GF Value™: zł13.56 vs. price of zł7.92 (41.6% below fair value)
  • GF Score™: 67/100 with 3 warning signs

No single metric tells the full story. See the WAR:SPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sopharma AD-Sofia Business Description

Other Exchanges 3JR:GermanySFA:Bulgaria
Address 5 Lachezar Stanchev Street, Sopharma Business Towers, Building A, Floor 12, Sofia, BGR, 1756
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products. It generates the majority of its revenue from the Distribution of pharmaceutical products.
67GF Score

Get the complete analysis for WAR:SPH

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł7.92
Price
zł13.56
GF Value